Drug, across the briefings

Rituximab across 4 cancers

Rituximab appears in 4 of the briefings; its FDA label names 3 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Chronic lymphocytic leukemia	label names disease	approved on MS4A1	183	14
Diffuse large B-cell lymphoma	label names disease	approved on MS4A1	185	42
Follicular lymphoma	label names disease	approved on MS4A1	186	33
Hodgkin lymphoma		approved on MS4A1	190	37

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.